FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Healio

FDA approves three new pediatric indications for once-weekly growth hormone injection

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
Yahoo Finance

Human Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035

Ottawa, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The global human growth hormone injection market size is calculated at USD 4.82 billion in 2026 and is expected to reach around USD 8.54 billion by 2035, ...
Southeast Missourian

FDA approves years of growth-hormone injections for short but h

WASHINGTON -- Children who are healthy but abnormally short will be able to have injections of growth hormone in hopes of gaining 1 to 3 more inches of height, the Food and Drug Administration said ...
Medscape

Children Born SGA on Growth Hormone Therapy Show Impaired Glucose Metabolism

Children born small for gestational age (SGA) exhibited impaired glucose-insulin metabolism, similar to children with obesity, which worsened under growth hormone therapy. In contrast, children with ...
Business Insider

How to boost hGH, the hormone linked to enhanced athletic performance that's illegal for most

Human growth hormone (hGH) is linked to muscle mass, weight loss, and increased athletic performance. You produce hGH naturally, but you can also get injections of recombinant growth hormone (rhGH).

Growth hormone receptor could serve as possible target for improving lung cancer treatment

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...